Human papillomavirus (HPV) vaccine programs in low- and middle-income countries face financial, programmatic, and social barriers to the introduction and sustainability of these programs. An HPV vaccine delivered through a microarray patch (MAP) could offer potential advantages to address some of those barriers. We asked global experts and stakeholders in Ethiopia about the acceptability and programmatic suitability of this option. In this report, we share the input from these stakeholders, both in terms of programmatic advantages and concerns regarding an HPV vaccine MAP, as well as some of their desired attributes.